Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products : workshop summary
- Denise Caruso, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
- data file.
- Washington, D.C. : National Academies Press, 
- Physical description
- 1 online resource (1 PDF file (xvi, 134 pages)) : illustrations
- Caruso, Denise, 1956- rapporteur.
- English, Rebecca A., rapporteur.
- Claiborne, Anne B., rapporteur.
- Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation, issuing body.
- Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products (Workshop) (2014 : White Oak, Md.)
- Includes bibliographical references.
- 1 Front Matter-- 2 1 Introduction-- 3 2 Identifying and Characterizing Uncertainty-- 4 3 The Regulators' Challenge-- 5 4 Basic Methodologies and Applications for Understanding and Evaluating Uncertainty-- 6 5 Communicating Uncertainty-- 7 6 Final Reflections on Ways to Characterize and Communicate Uncertainty-- 8 References-- 9 Appendix A: Workshop Agenda-- 10 Appendix B: FDA Case Studies-- 11 Appendix C: Bibliography-- 12 Appendix D: Participant Biographies.
- (source: Nielsen Book Data)
Despite the extensive body of evidence that informs regulatory decisions on pharmaceutical products, significant uncertainties persist, including the underlying variability in human biology, factors associated with the chemistry of a drug, and limitations in the research and clinical trial process itself that might limit the generalizability of results. As a result, regulatory reviewers are consistently required to draw conclusions about a drug's safety and efficacy from imperfect data. Efforts are underway within the drug development community to enhance the evaluation and communication of the benefits and risks associated with pharmaceutical products, aimed at increasing the predictability, transparency, and efficiency of pharmaceutical regulatory decision making. Effectively communicating regulatory decisions necessarily includes explanation of the impact of uncertainty on decision making. On February 12 and May 12, 2014, the Institute of Medicine's Forum on Drug Discovery, Development, and Translation held public workshops to advance the development of more systematic and structured approaches to characterize and communicate the sources of uncertainty in the assessment of benefits and risks, and to consider their implications for pharmaceutical regulatory decisions. Workshop presentations and discussions on February 12 were convened to explore the science of identifying and characterizing uncertainty in scientific evidence and approaches to translate uncertainties into decisions that reflect the values of stakeholders. The May 12 workshop presentations and discussions explored tools and approaches to communicating about scientific uncertainties to a range of stakeholders in the drug development process. Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products summarizes the presentation and discussion of both events. This report explores potential analytical and communication approaches and identifies key considerations on their development, evaluation, and incorporation into pharmaceutical benefit- risk assessment throughout the entire drug development lifecycle.
(source: Nielsen Book Data)
- Pharmaceutical policy > United States > Decision making > Congresses.
- Drugs > Law and legislation > United States > Decision making > Congresses.
- Drugs > Risk assessment > United States > Decision making > Congresses.
- Drugs > Testing > Government policy > United States > Congresses.
- Drugs > Testing > Law and legislation > United States > Congresses.
- Pharmaceutical Preparations.
- Risk Assessment.
- Drug Industry > standards.
- Legislation, Drug.
- United States.
- BUSINESS & ECONOMICS > Infrastructure.
- SOCIAL SCIENCE > General.
- Drugs > Testing > Government policy.
- Drugs > Testing > Law and legislation.
- United States.
- Publication date
- Title from PDF title page.
- Funding Information
- This activity was supported by contracts between the National Academy of Sciences and the U.S. Department of Health and Human Services (HHSN26300023 [Under Base #HHSN263201200074I] and HHSF22301026T [Under Base #HHSF223200810020I]), AbbVie Inc., American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, AstraZeneca, Burroughs Wellcome Fund, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly and Company, FasterCures, Friends of Cancer Research, GlaxoSmithKline, Johnson & Johnson, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Sanofi. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for the activity.